secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058209
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharma Q1 net loss $22.4M; pipeline data expected H2 2024
---------------------------------------------------------------

- Net loss $22.4M ($0.30 per share) vs $21.5M ($0.31) in Q1 2023; R&D expense $18.6M.
- Cash $240.7M at March 31, 2024, down from $263.4M; runway into 2026.
- Interim TERN-701 CARDINAL dose-escalation data expected 2H24; FDA Orphan Drug Designation granted.
- Top-line 28-day weight loss data from TERN-601 Phase 1 obesity trial expected 2H24.
- Leadership: Melita Sun Jung appointed CBO, Scott Harris appointed CDO; Erin Quirk departing as president/R&D head.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017024058209/0000950170-24-058209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017024058209/tern-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer